Mitigating jaw osteonecrosis: bioactive glass and pericardial membrane combination in a rat model.

Autor:	Pellicano AA; Laboratory of Neuroscience, Hospital Sírio-Libanês, São Paulo, SP, Brazil., Benites BM; Laboratory of Neuroscience, Hospital Sírio-Libanês, São Paulo, SP, Brazil., Paschoa AFN; Laboratory of Neuroscience, Hospital Sírio-Libanês, São Paulo, SP, Brazil., Oliveira LC; Department of Radiology and Oncology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil., Campos ACP; Laboratory of Neuroscience, Hospital Sírio-Libanês, São Paulo, SP, Brazil., Martins DO; Laboratory of Neuroscience, Hospital Sírio-Libanês, São Paulo, SP, Brazil., Real CC; Department of Radiology and Oncology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil., de Paula Faria D; Department of Radiology and Oncology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil., Fonseca FP; Department of Oral Surgery and Pathology, School of Dentistry, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil., Martinez RRC; Laboratory of Neuroscience, Hospital Sírio-Libanês, São Paulo, SP, Brazil.; LIM/23, Institute of Psychiatry, University of Sao Paulo School of Medicine, Sao Paulo, Brazil., Pagano RL; Laboratory of Neuroscience, Hospital Sírio-Libanês, São Paulo, SP, Brazil., Fregnani ER; Laboratory of Neuroscience, Hospital Sírio-Libanês, São Paulo, SP, Brazil.
Jazyk:	angličtina
Zdroj:	Frontiers in oncology [Front Oncol] 2024 May 10; Vol. 14, pp. 1348118. Date of Electronic Publication: 2024 May 10 (Print Publication: 2024).
DOI:	10.3389/fonc.2024.1348118
Abstrakt:	Objectives: Bisphosphonates (BFs) show clinical effectiveness in managing osteoporosis and bone metastases but pose risks of bisphosphonate-related jaw osteonecrosis (BRONJ). With no established gold standard for BRONJ treatment, our focus is on symptom severity reduction. We aimed to assess the preventive effects of bioactive glass and/or pericardial membrane in a preclinical BRONJ model, evaluating their potential to prevent osteonecrosis and bone loss post-tooth extractions in zoledronic acid (ZA)-treated animals. Methods: Rats, receiving ZA or saline biweekly for four weeks, underwent 1st and 2nd lower left molar extractions. Pericardial membrane alone or with F18 bioglass was applied post-extractions. Microarchitecture analysis and bone loss assessment utilized computerized microtomography (CT) and positron emission tomography (PET) with 18F-FDG and 18F-NaF tracers. Histological analysis evaluated bone injury. Results: Exclusive alveolar bone loss occurred post-extraction in the continuous ZA group, inducing osteonecrosis, osteolysis, osteomyelitis, and abscess formation. Concurrent pericardial membrane with F18 bioglass application prevented these outcomes. Baseline PET/CT scans showed no discernible uptake differences, but post-extraction 18F-FDG tracer imaging revealed heightened glucose metabolism at the extraction site in the ZA-treated group with membrane, contrasting the control group. Conclusion: These findings suggest pericardial membrane with F18 bioglass effectively prevents BRONJ in the preclinical model. Competing Interests: The authors declare the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Pellicano, Benites, Paschoa, Oliveira, Campos, Martins, Real, de Paula Faria, Fonseca, Martinez, Pagano and Fregnani.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu